ALKEM Alkem Lab Q1 FY27 results (Apr–Jun 2026) and concall
Alkem Laboratories reported a robust Q1 FY27 with an 11% YoY revenue growth to INR3,740 crores, driven by strong international sales and outperformance in the Indian market. Despite a 21.7% decline in net profit due to tax adjustments and operational expenses from new ventures like US CDMO, the company maintained a positive outlook on its core businesses and strategic initiatives. Management is actively addressing regulatory observations at its Daman facility and expects continued growth in its branded and international segments.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 10.9%, net profit down 22.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 +17% | 3,737 +11% | 3,603 +15% | 3,740 +11% |
| EBITDA | 753 | 759 | 391 | 739 | 921 +22% | 828 +9% | 517 +32% | 766 +4% |
| Net profit | 702 | 641 | 322 | 668 | 779 +11% | 653 +2% | 251 −22% | 521 −22% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
